A Phase 2 interventional study of Istaroxime and Placebo in Cardiogenic Shock, sponsored by Windtree Therapeutics. Completed at 13 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Windtree Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.
This is a pilot, multinational, multicenter, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of males or females 18 to 85 years of age, hospitalized for acute decompensated heart failure (ADHF) with persistent hypotension (systolic blood pressure [SBP] 70-100 mmHg for two hours).
Part A will dose all subjects for 24 hours with either 1.0 µg/kg/min or placebo; Part B will dose all subjects for 60 hours with two different regimens of istaroxime or placebo. Enrollment of Part A and Part B will be sequential.
Up to 30 sites in Part A; up to 15 sites in Part B. Sites may be located in Europe, Asia, South America, and North America.
296 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
This study's enrollment of 90 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Browse Shock, Cardiogenic studies →Windtree Therapeutics is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An admission for acute decompensated heart failure (ADHF) episode within 36 hours prior to randomization, defined as:
Persistent hypotension defined as:
Exclusion Criteria:
Laboratory exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min
Drug: Istaroxime
Placebo (lactose lyophilized powder) IV infusion for 24 hours
Drug: Placebo
Istaroxime IV infusion at 1.0 µg/kg/min for 6 hours, 0.5 µg/kg/min for 42 hours, 0.25 µg/kg/min for 12 hours.
Drug: Istaroxime
Istaroxime IV infusion at 0.5 µg/kg/min for 48 hours, followed by placebo IV infusion for 12 hours.
Drug: Istaroxime · Drug: Placebo
Placebo (lactose lyophilized powder) IV infusion for 60 hours.
Drug: Placebo
Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
Also known as: PST2744
Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
Also known as: Lactose lyophilized powder
Change from baseline in systolic blood pressure (SBP) area under the curve (AUC) 0-6
Change from baseline AUC for systolic blood pressure
Time frame: 0 to 6 hours after initiation of infusion
Change from baseline in SBP AUC 0-48
Change from baseline in AUC for systolic blood pressure in Part B
Time frame: 0 to 60 hours after initiation of infusion
Change from baseline in SBP AUC 0-60
Change from baseline in AUC for systolic blood pressure in Part B
Time frame: 0 to 48 hours after initiation of infusion
Treatment failure score
Treatment-failure score, based on death, circulatory, respiratory, or renal mechanical support or intravenous inotrope or vasopressor treatment, and changes in systolic blood pressure
Time frame: 60 hours from initiation of infusion
Change from baseline in SBP
Change from baseline in systolic blood pressure
Time frame: 6 hours after initiation of infusion
Change from baseline in SBP
Change from baseline in systolic blood pressure
Time frame: 24 hours after initiation of infusion
Change from baseline in SBP
Change from baseline in systolic blood pressure in Part B
Time frame: 48 hours after initiation of infusion
Change from baseline in SBP
Change from baseline in systolic blood pressure in Part B
Time frame: 60 hours after initiation of infusion
Number of treatment failures
Number of subjects requiring treatment with intravenous vasopressors, inotropes, and/or mechanical cardiac or renal support or have died
Time frame: Randomization to 24 hours for Part A
Number of treatment failures
Number of subjects requiring treatment with intravenous vasopressors, inotropes, and/or mechanical cardiac or renal support or have died
Time frame: Randomization to 48 hours for Part B
Number of treatment failures
Number of subjects requiring treatment with intravenous vasopressors, inotropes, and/or mechanical cardiac or renal support or have died
Time frame: Randomization to Day 5
Change in quality of life
Changes from baseline measured by the EQ-5D in Part A
Time frame: Baseline to Day 5 (96 hours) from infusion start
Change in quality of life
Changes from baseline measured by the EQ-5D in Part A
Time frame: Baseline to Day 30 from infusion start
Change in eGFR
Change from baseline and observed estimated glomerular filtration rate (eGFR)
Time frame: 24 hours from infusion start
Change in eGFR
Change from baseline and observed estimated glomerular filtration rate (eGFR)
Time frame: 48 hours from infusion start
Change in brain natriuretic peptide (BNP), N-terminal pro hormone B-type natriuretic peptide (NT-pro-BNP), troponin (cTn; either T or I) and venous lactate
Change from baseline and observed BNP, NT-pro-BNP, troponin (cTn; either T or I) and venous lactate
Time frame: 24 hours from infusion start
Change in brain natriuretic peptide (BNP), N-terminal pro hormone B-type natriuretic peptide (NT-pro-BNP), troponin (cTn; either T or I) and venous lactate
Change from baseline and observed BNP, NT-pro-BNP, troponin (cTn; either T or I) and venous lactate
Time frame: 48 hours from infusion start
Time to worsening heart failure (HF)
Time to worsening HF
Time frame: Up to Day 5
Time to HF re-admission or death
Time to HF re-admission or death
Time frame: Up to Day 30
Length of initial hospitalization
Length of initial hospitalization
Time frame: Up to Day 30
Days alive and out of the hospital
Days alive and out of the hospital
Time frame: Up to Day 30
Mortality and reasons for death
Mortality and reasons for death
Time frame: Up to Day 30
Change in coronary index (CI)
Change from baseline in CI as assessed by echocardiogram - Part A
Time frame: 24 hours
Change in E to e' ratio
Change from baseline in E to e' ratio as assessed by echocardiogram - Part A
Time frame: 24 hours
Change in stroke volume index (SVI)
Change from baseline in SVI as assessed by echocardiogram - Part A
Time frame: 24 hours
Change in left atrium area (LAA)
Change from baseline in LAA as assessed by echocardiogram - Part A
Time frame: 24 hours
Change in CI
Change from baseline in CI as assessed by echocardiogram - Part B
Time frame: 48 hours
Change in E to e' ratio
Change from baseline in E to e' ratio as assessed by echocardiogram - Part B
Time frame: 48 hours
Change in SVI
Change from baseline in SVI as assessed by echocardiogram - Part B
Time frame: 48 hours
Change in LAA
Change from baseline in LAA as assessed by echocardiogram - Part B
Time frame: 48 hours
Plan to share: No
Ran from Sep 2020 to primary completion in Sep 2024, 47 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Istaroxime
Windtree Therapeutics